TW224942B - - Google Patents

Info

Publication number
TW224942B
TW224942B TW080102419A TW80102419A TW224942B TW 224942 B TW224942 B TW 224942B TW 080102419 A TW080102419 A TW 080102419A TW 80102419 A TW80102419 A TW 80102419A TW 224942 B TW224942 B TW 224942B
Authority
TW
Taiwan
Prior art keywords
cataract
medicament
manufacture
treatment
ketoprostaglandin compound
Prior art date
Application number
TW080102419A
Other languages
English (en)
Chinese (zh)
Original Assignee
Adka Ueno Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adka Ueno Kk filed Critical Adka Ueno Kk
Application granted granted Critical
Publication of TW224942B publication Critical patent/TW224942B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW080102419A 1990-04-04 1991-03-28 TW224942B (ref)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP9089590 1990-04-04
JP22164690 1990-08-22
JP2931091 1991-01-29

Publications (1)

Publication Number Publication Date
TW224942B true TW224942B (ref) 1994-06-11

Family

ID=27286510

Family Applications (2)

Application Number Title Priority Date Filing Date
TW080102419A TW224942B (ref) 1990-04-04 1991-03-28
TW081106617A TW249226B (ref) 1990-04-04 1991-03-28

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW081106617A TW249226B (ref) 1990-04-04 1991-03-28

Country Status (11)

Country Link
US (2) US5212324A (ref)
EP (1) EP0453127B1 (ref)
KR (1) KR970005172B1 (ref)
AT (1) ATE169219T1 (ref)
AU (1) AU644148B2 (ref)
CA (1) CA2039420C (ref)
DE (1) DE69129921T2 (ref)
DK (1) DK0453127T3 (ref)
ES (1) ES2119762T3 (ref)
GR (1) GR3027666T3 (ref)
TW (2) TW224942B (ref)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW205508B (ref) * 1990-08-02 1993-05-11 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5328933A (en) * 1992-10-28 1994-07-12 Allergan, Inc. Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues
SE9303627D0 (sv) * 1993-11-03 1993-11-03 Kabi Pharmacia Ab Method and means for prevention of cataract
WO1995013827A1 (en) * 1993-11-19 1995-05-26 The University Of Sydney A method for preventing or controlling cataract
SE9403160D0 (sv) * 1994-09-21 1994-09-21 Pharmacia Ab Method and means for prevention and treatment of secondary cataract
CN102126998B (zh) * 1996-06-10 2013-06-12 苏坎波公司 内皮素拮抗剂
US6048895A (en) * 1997-09-09 2000-04-11 The Procter & Gamble Company Aromatic C16-C20 substituted tetrahydro prostaglandins useful as FP agonists
JP2001515882A (ja) * 1997-09-09 2001-09-25 ザ プロクター アンド ギャンブル カンパニー Ｆｐアゴニストとして有用な、芳香族のあるｃ１６〜ｃ２０が置換されたテトラヒドロプロスタグランジン類
PT978284E (pt) 1997-11-28 2008-10-07 Sucampo Ag Utilização de compostos 15-ceto-prostaglandina-e como antagonistas da endotelina
HUP0200258A2 (hu) 1999-03-05 2002-05-29 The Procter & Gamble Co. C16-telítetlen FP-szelektív prosztaglandin analógok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
TWI225398B (en) * 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
US6458836B1 (en) 2000-03-16 2002-10-01 Sucampo, A.G. Treatment of ocular hypertension and glaucoma
CA2402597C (en) * 2000-03-16 2011-04-26 Sucampo Ag Composition for use in treatment of ocular hypertension and glaucoma
WO2001070233A2 (en) 2000-03-24 2001-09-27 Sucampo Ag Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
US20020013294A1 (en) * 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
ATE433754T1 (de) 2000-04-06 2009-07-15 Sucampo Ag Gallensäurefördernde zusammensetzung für lebertransplantation welche ein 15-keto prostaglandin enthält
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
US20030060511A1 (en) * 2001-08-23 2003-03-27 Sucampo Ag Method for treatment of ocular hypertension and glaucoma
AU2002330747B2 (en) 2001-08-31 2007-07-19 Sucampo Ag Prostaglandin analogs as chloride channel opener
US8580851B2 (en) 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
PT1562604E (pt) * 2002-10-23 2012-04-09 Sucampo Ag Compostos de prostaglandina para o tratamento de obesidade
ES2591252T3 (es) 2002-12-27 2016-11-25 Sucampo Ag Derivados de prostaglandinas para tratar el síndrome de colon irritable y/o la dispepsia funcional
WO2005002588A1 (en) * 2003-07-03 2005-01-13 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI348386B (en) * 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
ES2431640T3 (es) 2003-08-21 2013-11-27 Sucampo Ag Composición oftálmica que comprende éster isopropílico de unoprostona y un agente de viscosidad
SE0303179D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
US7321057B2 (en) * 2004-08-02 2008-01-22 R-Tech Ueno, Ltd. Method for manufacturing prostaglandin analogue
RU2440338C2 (ru) 2005-01-27 2012-01-20 Сукампо Аг Способ и композиция для лечения заболеваний центральной нервной системы
WO2006093348A2 (en) * 2005-03-04 2006-09-08 Sucampo Ag Method and composition for treating peripheral vascular diseases
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US9241918B2 (en) 2005-03-16 2016-01-26 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
ES2371658T3 (es) * 2005-04-12 2012-01-05 Sucampo Ag Uso combinado de compuesto de prostaglandina e inhibidor de la bomba de protones para el tratamiento de trastornos gastrointestinales.
BRPI0707334B8 (pt) 2006-01-24 2021-05-25 R Tech Ueno Ltd formulação de cápsula de gelatina mole de um composto 15-ceto-prostaglandina e método para estabilização do um composto 15-cetoprostaglandina
KR20180027615A (ko) * 2006-01-24 2018-03-14 가부시키가이샤 아루떼꾸 우에노 바이-사이클릭 화합물을 함유하는 약학적 조성물 및 바이-사이클릭 화합물의 안정화 방법
EP1994933B1 (en) * 2006-03-13 2017-04-26 R-Tech Ueno, Ltd. Aqueous composition
US8871752B2 (en) * 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8609729B2 (en) 2009-04-15 2013-12-17 Sucampo Ag Method for treating macular degeneration
US8569279B2 (en) * 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
WO2012137987A1 (en) 2011-04-07 2012-10-11 Sucampo Ag Method for treating asthenopia
CN103841966A (zh) 2011-08-05 2014-06-04 苏坎波公司 治疗精神分裂症的方法
AR092821A1 (es) 2012-04-20 2015-05-06 Sucampo Ag Conjugado de derivado de acido graso-polimero
US20150057351A1 (en) 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain
WO2016203317A1 (en) 2015-06-19 2016-12-22 Sucampo Ag Pharmaceutical compositions comprising fatty acid derivative

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3505386A (en) * 1965-12-29 1970-04-07 Upjohn Co Compounds related to prostaglandins
US3974195A (en) * 1974-10-02 1976-08-10 The Upjohn Company 2A,2B-Dihomo-15-alkyl-PGF2.sub.α analogs
EP0153858A3 (en) * 1984-02-29 1985-12-11 The Upjohn Company The therapeutic use of prostaglandins
CA1323364C (en) * 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
EP0292177B1 (en) * 1987-05-15 1992-03-25 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Fervescence composition
ES2052735T3 (es) * 1987-09-18 1994-07-16 R Tech Ueno Ltd Un metodo para producir un agente hipotensor ocular.
GB2210556B (en) * 1987-10-02 1991-07-17 Ueno Seiyaku Oyo Kenkyujo Kk The use of 15-keto-16-halo-prostaglandins in cathartic compositions
JP2597629B2 (ja) * 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
AU619543B2 (en) * 1988-05-11 1992-01-30 Sucampo Ag Use of 15-ketoprostaglandin e or f compounds for uterine contraction
JP2597649B2 (ja) * 1988-05-11 1997-04-09 株式会社上野製薬応用研究所 気管・気管支拡張剤
DE68906193T2 (de) * 1988-05-23 1993-08-05 Ueno Seiyaku Oyo Kenkyujo Kk Hypersphyxia verursachende zusammensetzung.
AU604156B2 (en) * 1988-09-14 1990-12-06 R-Tech Ueno, Ltd. Prostaglandins of the F series
DE68928551T2 (de) * 1988-10-01 1998-04-23 Ueno Seiyaku Oyo Kenkyujo Kk Oculare hypotensive Mittel
TW205508B (ref) * 1990-08-02 1993-05-11 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo

Also Published As

Publication number Publication date
ATE169219T1 (de) 1998-08-15
US5686487A (en) 1997-11-11
GR3027666T3 (en) 1998-11-30
DE69129921T2 (de) 1999-01-14
AU644148B2 (en) 1993-12-02
KR970005172B1 (ko) 1997-04-14
KR910018027A (ko) 1991-11-30
CA2039420C (en) 1996-12-10
EP0453127A3 (en) 1992-12-09
EP0453127A2 (en) 1991-10-23
DK0453127T3 (da) 1998-10-26
CA2039420A1 (en) 1991-10-05
DE69129921D1 (de) 1998-09-10
US5212324A (en) 1993-05-18
EP0453127B1 (en) 1998-08-05
ES2119762T3 (es) 1998-10-16
TW249226B (ref) 1995-06-11
AU7404791A (en) 1991-10-10

Similar Documents

Publication Publication Date Title
TW249226B (ref)
DK0559413T3 (ref)
EP0435443A3 (en) Use of 15-keto-prostaglandin compound for improvement of encephalic function
EP0455448A3 (en) Treatment of pancreatic disease with 15-keto-prostaglandin compounds
EP0467564A3 (en) Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
ES2093774T3 (es) Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
SG86284A1 (en) Use of (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidineacetamide for the manufacture of medicaments for the treatment of anxiety
GR3018674T3 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
EP0430551A3 (en) Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
EP0430552A3 (en) Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
GR3022217T3 (en) Treatment of cataract with prostacyclin compounds
AU639322B2 (en) Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
GR3029726T3 (en) Use of a therapeutic compound for the treatment of bronchitis

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent